Novo Nordisk registers two Phase 1 PK trials for zenagamtide and NNC0537-1482

Novo Nordisk registered two new early-phase pharmacokinetic studies this week, both listed as not yet recruiting.

• Novo Nordisk registered a Phase 1 study (NCT07815067) of zenagamtide in people with overweight or obesity, with separate arms testing an oral tablet and a subcutaneous injection. The trial is randomized, parallel in design, with an estimated enrollment of 320 participants¹, and the tablet arm is meant to assess how meal timing and water volume at dosing affect how much zenagamtide enters the bloodstream¹.
• Novo Nordisk also registered a Phase 1 study (NCT07808788) of a single subcutaneous dose of NNC0537-1482 in people with chronic kidney disease. The study will compare how the medicine moves through the body in people with reduced kidney function versus normal kidney function², enrolling an estimated 54 participants in a single treatment group².